or at least Edge to see the coolest products on Steemhunt.
'),document.write("\x3c!--"),document.execCommand("Stop"))A novel long-acting glycopegylated fibroblast growth factor 21 analogue; the BIO89-100 Treatment for Liver & Metabolic Disorders could become a therapy for NASH (nonalcoholic steatohepatitis) given its ability to address the key liver pathologies (steatosis & fibrosis) & underlying metabolic dysregulation in NASH patients.
$0.00·0 votes· comments
You need a Steem account to join the discussion
Sign up now